Companies
(73)
AAC Clyde Space
ALM Equity
Alzinova
Arion Bank
Arlandastad Group
Ascelia Pharma
Bactiguard
Bergman & Beving
Besqab
BioPorto
Björn Borg
Bokusgruppen
Bonava
BTS Group
Byggmästaren
CAG Group
Calviks
Carasent
CDON
Clavister
Clemondo Group
eEducation Albert
Elanders
Elicera Therapeutics
Eolus
Ependion
EQL Pharma
Faron Pharmaceuticals
FluoGuide
Gentoo Media
GiG Software
HAKI Safety
HANZA
Iconovo
Idun Industrier
InfraCom
Initiator Pharma
Intervacc
ITAB Group
Kebni
Lifecare ASA
Lindex Group
Logistri
Lumi Education Group
Lytix Biopharma
Medivir
Mentice
Micro Systemation
MilDef Group
Net Insight
Nordic LEVEL Group
Orexo
Ortoma
OssDsign
Paxman
Pierce
PowerCell
Pricer
Qualisys
Relais Group
SaltX
Scanfil
Sensys Gatso Group
Sleep Cycle
Solar Foods
Spago Nanomedical
Svedbergs Group
Taaleri
Terranor
Vertiseit
Vivesto
W5 Solutions
Waystream
Sweden
Healthcare
Latest share price
SEK
20 Nov 2026 17:29 CET
Fair value range
SEK
23 Oct 2026
Market cap
SEK
m
Bactiguard
Healthcare
2026-10-23
Net sales grew 21% Y/Y to SEK55m, with licence revenue of SEK41m, while adj. EBITDA reached SEK20m, corresponding to a margin of 34%. 9M adj. EBITDA of SEK31m already...
Post-Results Note
Kristofer Liljeberg
Maria Karlsson Osipova
Licence engine gaining momentum - Q3 review
Strong BD and stronger EBITDA - Q3 initial
Further progress towards stability expected - Q3 preview
Bactiguard
Healthcare
2026-10-22
Net sales of SEK55m were 6% above our estimate (+21% Y/Y, +24% at CER), while adj. EBITDA of SEK20m was more than double our SEK9m, giving a 34% margin vs our 17%...
News
Kristofer Liljeberg
Maria Karlsson Osipova
Licence engine gaining momentum - Q3 review
Strong BD and stronger EBITDA - Q3 initial
Further progress towards stability expected - Q3 preview
Bactiguard
Healthcare
2026-10-01
We expect further progress towards stability in Q3, forecasting net sales of SEK52m, corresponding to c14% Y/Y growth (including a <1%-point FX effect), and EBITDA of...
Pre-Results Note
Kristofer Liljeberg
Maria Karlsson Osipova
Licence engine gaining momentum - Q3 review
Strong BD and stronger EBITDA - Q3 initial
Further progress towards stability expected - Q3 preview
Price
Fair range high value
Fair range low value
Year
2024
2025
2026e
2027e
2028e
EPS
-0.85
-0.22
-0.30
-0.26
-0.03
EPS (Adj.)
-0.85
-0.22
-0.07
-0.14
-0.03
Sales Growth
19.89%
-10.60%
-3.36%
14.22%
14.97%
EPS Growth (Adj.)
-35.00%
421.19%
90.36%
P/E
P/E (Adj.)
EV/EBITA
-21.1
-186.9
-50.0
-93.6
141.3
EV/EBITDA
34.2
14.1
17.9
12.4
7.9
Learn more
Sector
Healthcare
Country
Sweden
Tickers
BACTIB@SS, BACTIb.ST
CEO
Christine Lind
CFO
Patrick Bach
Webpage
www.bactiguard.com
About DNB Carnegie Access
DNB Carnegie Access aim is to connect listed companies with the capital markets. Through top ranked public equity research and broad distribution via written reports, seminars, video, and podcasts, we increase visibility and investor understanding for small- and medium-sized companies, both among institutional and private investors.
Along with corporate finance, market making and certified advisory we provide a complete product offering to our clients.
Private Banking
Tailored wealth management. Your financial future, personalized.
Montrose
A digital investment platform designed for passionate investors.
DNB Carnegie
Leading Nordic investment bank and wealth management.
© Copyright DNB Carnegie Investment Bank AB